Treatment of Early Age Mania - Full Text View

Purpose

This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.

Condition	Intervention	Phase
Bipolar Disorder	Drug: Lithium carbonate Drug: Valproate Drug: Risperidone	Phase III

MedlinePlus related topics:

Bipolar Disorder

ChemIDplus related topics:

Risperidone Divalproex sodium Valproate Sodium Valproic acid Lithium carbonate Lithium citrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Treatment of Early Age Mania (TEAM) Study

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:

Clinical Global Impressions-Bipolar [ Time Frame: Measured at Week 8 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Side Effects for Children and Adolescents [ Time Frame: Measured at Week 8 ] [ Designated as safety issue: Yes ]
Mania Rating Scale [ Time Frame: Measured at Week 8 ] [ Designated as safety issue: No ]

Estimated Enrollment:	400
Study Start Date:	February 2003
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Participants will receive treatment with lithium for 8 to 16 weeks	Drug: Lithium carbonate Titrated until blood level is 1.1 to 1.3 mEq/L
2: Experimental Participants will receive treatment with valproate for 8 to 16 weeks	Drug: Valproate Titrated until blood level is 111 to 125 ug/mL
3: Experimental Participants will receive treatment with risperidone for 8 to 16 weeks	Drug: Risperidone Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID

Detailed Description:

Patients are randomly assigned to receive lithium (Eskalith), valproate (Depakote), or risperidone (Risperdal) for 8 to 16 weeks. They will have weekly visits to monitor their response to the medication. When the study is complete, care will be transferred to the child's treating psychiatrist.

Eligibility

Ages Eligible for Study:	6 Years to 15 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

DSM-IV criteria for bipolar I (manic or mixed) or mania for at least 4 weeks
CGAS less than or equal to 60
Good physical health

Exclusion Criteria:

Schizophrenia or any pervasive developmental disorder
Major medical or neurological disease
History of addiction to illicit substances or alcohol or drug abuse within the last 4 weeks
IQ less than 70
Pregnancy or breast-feeding
Unacceptable methods of contraception
In-patient care at baseline

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00057681

Contacts


Contact: Barbara Geller, MD		gellerb@medicine.wustl.edu

Locations


United States, District of Columbia
	Children's National Medical Center	Recruiting
	Washington, District of Columbia, United States, 20010
	Contact: Thalia Attinger 202-884-2681 pjoshi@cnmc.org
	Principal Investigator: Paramjit Joshi, MD

United States, Maryland
	Johns Hopkins Medical Center	Recruiting
	Baltimore, Maryland, United States, 21287
	Contact: Sam Walford, MA 410-955-1542 swalford@jhmi.edu
	Principal Investigator: John Walkup, MD

United States, Missouri
	Washington University School of Medicine	Recruiting
	St. Louis, Missouri, United States, 63110-1093
	Contact: Samantha Blankenship, MSW 314-286-2783 blankens@msnotes.wustl.edu
	Principal Investigator: Joan Luby, MD

United States, Pennsylvania
	University of Pittsburgh/WPIC	Recruiting
	Pittsburgh, Pennsylvania, United States, 15208
	Contact: Annette Baughman 800-518-0370 baughmanam@msx.upmc.edu
	Principal Investigator: David Axelson, MD

United States, Texas
	University of Texas	Recruiting
	Galveston, Texas, United States, 77555
	Contact: Jennifer Ferguson, MSW 281-335-5403 jdfergus@utmb.edu
	Principal Investigator: Karen Wagner, MD

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators


Principal Investigator:	Barbara Geller, MD	Washington University in St. Louis

More Information

Publications indexed to this study:

Tillman R, Geller B. Diagnostic characteristics of child bipolar I disorder: does the "Treatment of Early Age Mania (team)" sample generalize? J Clin Psychiatry. 2007 Feb;68(2):307-14.

Responsible Party:	Washington University in St. Louis ( Barbara Geller, MD )
Study ID Numbers:	U01 MH64846, DDTR B4-ARM, U01 MH64851, U01 MH64911, U01 MH64868, U01 MH64887, U01 MH64850, U01 MH64869, DPTR B4-ARM
First Received:	April 4, 2003
Last Updated:	February 13, 2008
ClinicalTrials.gov Identifier:	NCT00057681
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

Mania

Study placed in the following topic categories:

Affective Disorders, Psychotic

Dopamine

Bipolar Disorder

Risperidone

Mood Disorders

Lithium Carbonate

Psychotic Disorders

Valproic Acid

Serotonin

Lithium

Additional relevant MeSH terms:

Neurotransmitter Agents

Tranquilizing Agents

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Psychotropic Drugs

Central Nervous System Depressants

Dopamine Antagonists

Enzyme Inhibitors

Antimanic Agents

Antipsychotic Agents

Pharmacologic Actions

Serotonin Antagonists

Serotonin Agents

Mental Disorders

Therapeutic Uses

Dopamine Agents

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on July 03, 2008

Sponsored by:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00057681